pf-06463922 and Thoracic-Neoplasms

pf-06463922 has been researched along with Thoracic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for pf-06463922 and Thoracic-Neoplasms

Article	Year
Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors. Journal of pediatric hematology/oncology, 2021, 07-01, Volume: 43, Issue:5 Most inflammatory myofibroblastic tumors (IMTs) harbor ALK fusions but oncogene fusions involving ROS1, RET, NTRK, and PDGFR also occur. The recognition that most IMTs harbor receptor tyrosine kinase fusions has provided a rationale for the use of tyrosine kinase inhibitors to target these oncogenic drivers in advanced IMTs. Crizotinib has been effective in ALK and ROS1-positive IMTs but resistance eventually develops. Here we report the successful use of lorlatinib in a patient with heavily pretreated ROS1-positive IMT of the chest wall with acquired crizotinib-resistance and metastasis to the brain. Topics: Adolescent; Aminopyridines; Antineoplastic Agents; Brain; Brain Neoplasms; Humans; Lactams; Male; Myofibroblasts; Neoplasms, Muscle Tissue; Oncogene Proteins, Fusion; Protein-Tyrosine Kinases; Proteins; Proto-Oncogene Proteins; Pyrazoles; Thoracic Neoplasms	2021

Article

Year

Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors.

Journal of pediatric hematology/oncology, 2021, 07-01, Volume: 43, Issue:5

Most inflammatory myofibroblastic tumors (IMTs) harbor ALK fusions but oncogene fusions involving ROS1, RET, NTRK, and PDGFR also occur. The recognition that most IMTs harbor receptor tyrosine kinase fusions has provided a rationale for the use of tyrosine kinase inhibitors to target these oncogenic drivers in advanced IMTs. Crizotinib has been effective in ALK and ROS1-positive IMTs but resistance eventually develops. Here we report the successful use of lorlatinib in a patient with heavily pretreated ROS1-positive IMT of the chest wall with acquired crizotinib-resistance and metastasis to the brain.

Topics: Adolescent; Aminopyridines; Antineoplastic Agents; Brain; Brain Neoplasms; Humans; Lactams; Male; Myofibroblasts; Neoplasms, Muscle Tissue; Oncogene Proteins, Fusion; Protein-Tyrosine Kinases; Proteins; Proto-Oncogene Proteins; Pyrazoles; Thoracic Neoplasms

2021